We are live on ! Find out more
LXRX icon

Lexicon Pharmaceuticals
LXRX

102 hedge funds and large institutions have $1.12B invested in Lexicon Pharmaceuticals in 2013 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 37 increasing their positions, 27 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

37% more repeat investments, than reductions

Existing positions increased: 37 | Existing positions reduced: 27

10% more capital invested

Capital invested by funds: $1.02B → $1.12B (+$100M)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

0% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 8

1% less funds holding

Funds holding: 103 → 102 (-1)

Holders
102
Holders Change
-1
Holders Change %
-0.97%
% of All Funds
3.31%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.06%
New
8
Increased
37
Reduced
27
Closed
8
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
UBS AM
UBS AM
Illinois
+$11.9M
2
TRSOTSOK
Teachers Retirement System of the State of Kentucky
Kentucky
+$4.86M
3
BFA
BlackRock Fund Advisors
California
+$3.45M
4
Norges Bank
Norges Bank
Norway
+$990K
5
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale
Germany
+$686K

Top Sellers

1
Vanguard Group
Vanguard Group
Pennsylvania
-$4.62M
2
Allianz Asset Management
Allianz Asset Management
Germany
-$3.64M
3
Morgan Stanley
Morgan Stanley
New York
-$2.88M
4
Franklin Resources
Franklin Resources
California
-$1.57M
5
JP Morgan Chase
JP Morgan Chase
New York
-$1.47M
Name Holding Trade Value Shares
Change 		Change in
Stake
Prudential Financial
76
Prudential Financial
New Jersey
$54K -$9.11K -543 -14%
GC
77
Guggenheim Capital
Illinois
$52K +$5.28K +315 +11%
Ameriprise
78
Ameriprise
Minnesota
$50K +$1.76K +105 +4%
SB
79
Suntrust Banks
Georgia
$46K +$2.75K +164 +6%
WAM
80
World Asset Management
Michigan
$43K -$61K -3,638 -59%
AIP
81
Ameritas Investment Partners
Nebraska
$42K +$42.8K +2,553 New
Commonwealth Equity Services
82
Commonwealth Equity Services
Massachusetts
$41K -$2.4K -143 -6%
RFC
83
Russell Frank Company
Washington
$39K +$10.4K +623 +36%
Barclays
84
Barclays
United Kingdom
$36K -$2K -119 -4%
GCIA
85
Gabelli & Co Investment Advisers
New York
$36K – – –
CCM
86
Chilton Capital Management
Texas
$33.3K – – –
NCCM
87
Nine Chapters Capital Management
New Jersey
$33K +$33.1K +1,971 New
Royal Bank of Canada
88
Royal Bank of Canada
Ontario, Canada
$31K +$29.9K +1,781 +1,915%
JG
89
Jefferies Group
New York
$30K +$30.1K +1,797 New
PA
90
Profund Advisors
Maryland
$28K +$922 +55 +3%
WS
91
Wedbush Securities
California
$24K – – –
MAA
92
Managed Account Advisors
New Jersey
$18K +$6.36K +379 +55%
HI
93
Hudock Inc
Pennsylvania
$17K – – –
BlackRock
94
BlackRock
New York
$14K – – –
SFPIA
95
Stevens First Principles Investment Advisors
California
$12K -$4.8K -286 -29%
PAM
96
Panagora Asset Management
Massachusetts
$10K – – –
SO
97
STRS Ohio
Ohio
$7K – – –
Wells Fargo
98
Wells Fargo
California
$4K +$587 +35 +16%
TRCT
99
Tower Research Capital (TRC)
New York
$3K -$4.43K -264 -62%
Northwestern Mutual Wealth Management
100
Northwestern Mutual Wealth Management
Wisconsin
$1K – – –
1 2 3
4
5

LXRX Hedge Fund Activity: Q3 2013 in Review

102 of the 3,084 institutional investors tracked by Wall St. Rank reported a position in Lexicon Pharmaceuticals (LXRX) for Q3 2013, worth a combined $1.12B — up 9.9% from $1.02B a quarter earlier.

Fund positioning in LXRX was balanced in Q3 2013: 8 funds opened new positions, 8 closed out, 37 added to existing stakes and 27 trimmed.

The largest buyer was UBS AM, adding an estimated $11.9M. The largest seller was Vanguard Group, cutting an estimated $4.62M.

  • 102 institutional investors held Lexicon Pharmaceuticals (LXRX) as of Q3 2013, down from 103 in Q2 2013.
  • Funds reported $1.12B of Lexicon Pharmaceuticals stock for Q3 2013, up 9.9% quarter-over-quarter.
  • 8 funds opened new Lexicon Pharmaceuticals positions in Q3 2013 and 8 closed out, a net change of 0 holders.
  • The largest Lexicon Pharmaceuticals buyer in Q3 2013 was UBS AM, an estimated $11.9M added.
  • The largest Lexicon Pharmaceuticals seller in Q3 2013 was Vanguard Group, an estimated $4.62M sold.

Based on aggregated 13F filings for Q3 2013.